慢性乙型病毒性肝炎血清三叶因子3水平观察及其在不同中医证型中的差异性表达
Observation on serum level of trefoil factor 3 in patients with chronic hepatitis B and its differential expression in different TCM syndromes
- 上海中医药杂志 2021年55卷第6期 页码：46-49
- 作者机构：
1.上海中医药大学附属龙华医院脾胃病二科（上海 200120）
2.上海中医药大学附属龙华医院脾胃病研究所（上海 200032）
- 作者简介：
王月姣，女，硕士，主要从事慢性肝病的防治工作
邢练军，主任医师，博士研究生导师；E-mail：xingdoctor126.com
- 基金信息：国家自然科学基金资助项目(81573894);上海中医药大学附属龙华医院爱建捐赠基金资助项目(AJ044)
DOI：10.16305/j.1007-1334.2021.2003230
中图分类号：
扫 描 看 全 文
王月姣, 宋海燕, 张海燕, 等. 慢性乙型病毒性肝炎血清三叶因子3水平观察及其在不同中医证型中的差异性表达[J]. 上海中医药杂志, 2021,55(6):46-49.
Yuejiao WANG, Haiyan SONG, Haiyan ZHANG, et al. Observation on serum level of trefoil factor 3 in patients with chronic hepatitis B and its differential expression in different TCM syndromes[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(6):46-49.
王月姣, 宋海燕, 张海燕, 等. 慢性乙型病毒性肝炎血清三叶因子3水平观察及其在不同中医证型中的差异性表达[J]. 上海中医药杂志, 2021,55(6):46-49. DOI： 10.16305/j.1007-1334.2021.2003230.
Yuejiao WANG, Haiyan SONG, Haiyan ZHANG, et al. Observation on serum level of trefoil factor 3 in patients with chronic hepatitis B and its differential expression in different TCM syndromes[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(6):46-49. DOI： 10.16305/j.1007-1334.2021.2003230.
摘要
目的,2,研究慢性乙型病毒性肝炎（以下简称“慢乙肝”）血清三叶因子（trefoil factor, TFF）3水平及其在不同中医证型中的差异性表达，探索慢乙肝诊疗新靶标，助力慢乙肝中医辨证客观化。,方法,2,将150例慢乙肝患者设为慢乙肝组，40例健康对照者设为健康对照组，然后根据肝功能水平将150例慢乙肝患者分为肝功能正常组（36例）和肝功能异常组（114例），最后对肝功能异常的114例慢乙肝患者进行中医辨证，并据此分为虚证组（59例）和实证组（55例）。采用全自动生化分析仪测定肝功能，ELISA法检测TFF3、炎症因子水平，比较慢乙肝患者与健康对照者、不同肝功能水平慢乙肝患者、不同中医证型慢乙肝患者的血清TFF3水平，并分析肝功能、炎症因子与血清TFF3的相关性。,结果,2,①与健康对照组比较，慢乙肝组患者血清TFF3水平升高（,P,<,0.01）；与慢乙肝虚证患者比较，慢乙肝实证患者血清TFF3水平降低（,P,<,0.05）；不同肝功能水平的慢乙肝患者血清TFF3水平比较，差异无统计学意义（,P,>,0.05）。②相关性研究结果显示，慢乙肝患者血清TFF3水平与丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、肿瘤坏死因子-α（TNF-α）水平不具有相关性，与白介素-10（IL-10）、白介素-1β（IL-1β）水平呈正相关，但相关系数较低（,r,=0.193，,P,=0.020；,r,=0.223，,P,=0.007）。,结论,2,TFF3在慢乙肝患者血清中的表达水平升高，且虚证患者较实证患者更为明显；推测TFF3可能参与慢乙肝免疫应答调控，有望成为慢乙肝的诊疗新靶标及中医辨证的客观化依据。
Abstract
Objective,2,To study the serum level of trefoil factor (TFF) 3 in patients with chronic hepatitis B (CHB) and its differential expression in different traditional Chinese medicine (TCM) syndromes, explore new targets for diagnosis and treatment of CHB, and help the objectification of TCM syndrome differentiation of CHB.,Methods,2,First, 150 patients with CHB were set as CHB group, and 40 healthy people were set as healthy control group. Then, 150 patients with CHB were divided into normal liver function group (,n,=36) and abnormal liver function group (,n,=114) according to the condition of liver function. Finally, 114 patients with abnormal liver function were divided into deficiency syndrome group (,n,=59) and excess syndrome group (,n,=55) according to TCM syndrome differentiation. We used automatic biochemical analyzer to measure liver function, ELISA to detect the levels of TFF3 and inflammatory factors, compared the serum level of TFF3 in CHB patients with that in healthy controls, CHB patients with different liver function levels, and CHB patients with different TCM syndromes, and analyzed the correlation between liver function, inflammatory factors and serum TFF3.,Results,2,①The serum level of TFF3 in patients with CHB increased compared with that of healthy controls (,P,<,0.01). The serum level of TFF3 in CHB patients of the excess syndrome group decreased compared with that in patients of the deficiency syndrome group (,P,<,0.05). There was no significant difference in serum level of TFF3 among CHB patients with different liver function levels (,P,>,0.05).②The results of correlation study showed that serum level of TFF3 in CHB patients had no correlation with levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and tumor necrosis factor-α (TNF-α), while it was positively correlated with interleukin-10 (IL-10) and interleukin-1β (IL-1β) levels with low the correlation coefficient (,r,=0.193,P,=0.020; ,r,=0.223,P,=0.007).,Conclusion,2,The serum expression level of TFF3 in CHB patients rises, which could be observed more obviously in patients with deficiency syndrome than in those with excess syndrome. It is speculated that TFF3 may be involved in the regulation of immune response of CHB, which is expected to become a new target for diagnosis and treatment of CHB and an objective basis for TCM syndrome differentiation.
关键词
慢性乙型病毒性肝炎血清三叶因子3中医证型肝功能炎症因子
Keywords
chronic hepatitis Bserum trefoil factor 3TCM syndromeliver functioninflammatory factor
references
丁叶舟，王晖. 乙肝防治指南在我国临床应用中的现状和思考[J]. 胃肠病学和肝病学杂志，2018, 27(9): 972-975.
沈锋，程张军. 精准医学和大数据时代对肝癌临床研究的认识[J]. 中国实用外科杂志，2016, 36(6): 599-602.
World Health Organization.Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection[M].Geneva: World Health Organization, 2015: 25-35.
European Association for the Study of the Liver.EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J]. J Hepatol, 2016, 57(1): 167-185.
朱文峰.中医诊断学[M]. 北京：中国中医药出版社，2002: 148-149.
贺劲松，周大桥，童光东，等. 补肾健脾胶囊治疗慢性乙肝病毒携带者的随机双盲实验[J]. 中国实验方剂学杂志，2010, 16(6): 246-249.
邢宇锋，张晓晖，陈英杰，等. 慢性乙肝病毒携带者中医证候分布规律调查及病机探讨[J]. 中西医结合肝病杂志，2012, 22(4): 196-199.
姚红梅，姜锦林.慢性乙型肝炎的中医药治疗近况[J]. 世界最新医学信息文摘，2018, 18(58): 54-55.
SUEMORI S, LYNCH-DEVANEY K, PODOLSKY D K.Identification and characterization of rat intestinal trefoil factor: tissue-and cell-specific member of the trefoil protein family[J]. Proc Natl Acad Sci U S A, 1991, 88(24): 11017-11021.
TAUPIN D, PEDERSEN J, FAMILARI M, et al.Augmented intestinal trefoil factor (TFF3) and loss of pS2 (TFF1) expression precedes metaplastic differentiation of gastric epithelium[J]. Lab Invest, 2001, 81(3): 397-408.
KJELLEV S.The trefoil factor family-small peptides with multiple functionalities[J]. Cell Mol Life Sci, 2009, 66(8): 1350-1369.
MASHIMO H, WU D C, PODOLSKY D K,et al.Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor[J]. Science, 1996, 274(5285): 262-265.
张秋宁，马力. 三叶因子3在胃癌组织中的表达及与血管形成的关系[J]. 现代肿瘤医学，2005, 13(1): 42-44.
王琳，黄建坤.TFF3作为肿瘤生物标志物的研究[J]. 肿瘤防治研究，2015, 42(11): 1156-1160.
NELSON D R, COOPER J N, LALEZARI J P, et al.All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 Phase Ⅲ Study[J]. Hematology, 2015, 61(4): 1127-1135.
崔恬冰，邢练军，季光，等. 三叶因子3在消化系统疾病中的作用[J]. 中国新药与临床杂志，2018, 37(5): 249-254
中华医学会感染病学分会，中华医学会肝病学分会.慢性乙型肝炎防治指南（2019年版）[J]. 中国医学前沿杂志（电子版），2019, 11(12): 51-77.
中华中医药学会肝病分会. 病毒性肝炎中医辨证标准（2017年版）[J]. 中西医结合肝病杂志，2017, 27(3): 193-194.
PODOLSKY D K, GERKEN G, EYKING A, et al.Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency[J]. Gastroenterology, 2009, 137(1):209-220.
KIMURA Y, LEUNG P S, KENNY T P, et al.Differential expression of intestinal trefoil factor in biliary epithelial cells of primary biliary cirrhosis[J]. Hepatology, 2002, 36(5): 1227-1235.
KJELLEV S, THIM L, PYKE C, et al.Cellular localization，binding sites，and pharmacologic effects of TFF3 in experimental colitis in mice[J]. Dig Dis Sci, 2007, 52(4): 1050-1059.
陈美娅，张靖，任建林. 三叶因子3研究进展[J]. 世界华人消化杂志，2008, 20(16): 2267-2273.
BUJAK M, BUJAK IT, SOBOČANEC S, et al.Trefoil factor 3 deficiency affects liver lipid metabolism[J]. Cell Physiol Biochem, 2018, 47(2): 827-841.
ZHU Y, ZHAO S, DENG Y, et al. Hepatic GALE regulates whole-body glucose homeostasis by modulating TFF3 expression[J]. Diabetes, 2017, 66(11): 2789-2799.
王卫彬，李咏茵，侯金林. 慢性乙型肝炎患者抗病毒治疗过程中的免疫应答特点[J]. 临床肝胆病杂志，2016, 32(10): 1858-1862.
RAJA S B, MURLI M R, DEVARAJ H, et al. Differential expression of gastric MUC5AC in colonic epithelial cells: TFF3-wired IL1 beta/Akt crosstalk-induced mucosal immune response against Shigella dysenteriae infection[J]. J Cell Sci, 2012, 125(Pt3): 703-713.
卓锦蓝，龚先琼. 慢性乙型肝炎中医证型研究[J]. 医学信息，2020, 33(3): 43-45.
0
浏览量
122
下载量
0
CSCD
0
CNKI被引量
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 沪ICP备13044091号
沪公网安备 31011502015228号 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
- 总访问量：70551 今日访问量：32